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ABSTRACT 
Objective: Adverse drug reaction (ADR) is regarded as one of the major challenges in the treatment of drug-resistant tuberculosis (DR-TB). It can 
lead to non-compliance or interrupting treatment completion, which can contribute to avoidable morbidity, drug resistance, treatment failure, 
reduced quality of life, or mortality.  
Methods: A retrospective cohort study was conducted in the Ernakulam district of Kerala from 2016 to 2019. All DR-TB patients registered under 
the DR-TB center were enrolled in the study. Due to privacy and confidentiality HIV infected patients and patients below 12 y of age were excluded 
in this study and only the data with ADR reported by patients is collected from medical records.  
Results: Out of the total 146 patients, about 75 % of patients experienced at least one ADR during treatment, and a total of 208 ADRs were reported. 
Among all the ADRs, the most common ADR was gastritis (12.98%) followed by ototoxicity (10%) and vomiting (5.76%), etc. It was found that 
males (78.76%) within the age group 46-65 y exhibited more ADR than females. Some of the ADR requires drug withdrawal and replacement with 
other drugs and most of the patients also needed symptomatic treatment without modifying the treatment regimen. All ADR reported were 
collected and causality assessment was done via WHO and Naranjo scale. The majority of ADR belongs to the “probable” category in the WHO scale 
and Naranjo scale. The evaluation of the severity of ADR by using the Modified Hartwig and Siegel scale indicated that most of the ADR was of 
moderate level showing a 4b reaction. The study also assessed the preventability of ADR using the Schumock and Thornton preventability scale. 
Conclusion: Many of the ADRs were unidentified or not reported due to several reasons like milder ADR, patient lack of knowledge, Negligence of 
symptoms, unawareness of health providers, etc. Whereas the long-term treatment and diversities in age, gender, etc. were found as major 
contributors to ADR along with comorbidities. New drugs in combination with existing drugs created the potential for previously unnotified 
reactions. Pharmacovigilance should address the safety of therapy and identify ADRs, especially the serious ones with routine monitoring to prevent 
mortality, morbidity, and other negative outcomes. 
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INTRODUCTION 
Tuberculosis, an infectious disease caused by Mycobacterium 
tuberculosis with inappropriate treatment can increase the risk of 
treatment failure, relapse, and drug resistance [1]. Drug resistance 
TB(DR-TB) is an alarming obstacle to effective TB treatment and 
prevention [2] and it occurs when the bacteria become resistant to 
at least isoniazid and rifampicin, the two most powerful anti-TB 
drugs. A rare type of DR-TB observed is called, extensively drug-
resistant TB (XDR-TB) which is resistant to isoniazid, rifampicin, any 
fluoroquinolones, and at least one of three second-line injectable 
drugs (i.e., kanamycin, capreomycin, amikacin) [3]. 
Drug susceptible TB is treated with regimens containing first-line drugs 
(FLDs’) whereas treatment of DR-TB requires a regimen comprising 
both second-line drugs (SLDs’), a few FLDs’, some add on agents 
(Bedaquiline and Delamanid) [4] and thus is associated with an 
increased incidence of adverse drug reactions (ADR). The incidence of 
ADR during treatment may vary from 5% to 52% [5]. The drug-resistant 
strain requires a prolonged duration of therapy with second-line drugs 
which are highly toxic and less effective, as a result, adverse drug 
reactions are very common during treatment [6]. The severity of the 
reaction can range from mild which does not require immediate 
modification of standardized regimen and it can be continued with the 
help of a supportive drug to the more severe or life-threatening 
condition where alteration or even discontinuation of the treatment is 
required [7]. ADRs were determined by clinical criteria or laboratory 
data documented in the patient chart [8]. The following lab parameters 
have to be investigated such as renal function test, Liver function test, 
Thyroid function test, Complete blood count, and Audiometry every 
three months during treatment to define the ADR [6]. 
ADR is regarded as one of the major causes of patient noncompliance 
to the treatment and there may be a higher risk of treatment failure 
and default, finally affecting outcome [9]. If the ADR is not properly 
monitored, it becomes irreversible resulting in disability or permanent 
damage, therefore it is imperative to monitor and treat the ADR in a 
systemic and timely manner [6]. To attain better patient compliance 
and to boost the treatment results, documentation of drug events is 
necessary along with its assessment and management [8]. This study 
aims to monitor the occurrence of adverse drug reactions in patients 
of DR-TB and to assess the causality, severity, and preventability of 
reported adverse drug reactions.  
MATERIALS AND METHODS 
Study design and setting 
A multi-center retrospective cohort study was undertaken at 
Ernakulam district, Kerala from 2016 to 2019 among DR-TB 
patients. All the DR-TB patients registered under the district 
tuberculosis center (DTC), Ernakulam (which includes 8 TB units 
with 16-18 subunits) were enrolled in the study. The study involves 
a detailed evaluation of patient records for ADR maintained by the 
Revised National Tuberculosis Control Programme (RNTCP) in the 
government sector and the medical records were sorted and 
selected according to the inclusion and exclusion criteria. The 
inclusion criteria were the patients registered under RNTCP in 
Ernakulam district from 2016-2019 with an age greater than 12 y 
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and the study excluded patients with HIV, as access to DR-TB 
patients with HIV, was denied due to sensitive social data. 
Data collection 
The retrospectively collected data were extracted from medical 
records of DR-TB patients, and as it involved only the reviewing of 
treatment files, informed consent was not mandatory. All reported 
ADR were documented in a digital sheet (Excel 2016) which 
consisted of age, sex, comorbidity, duration, causative agent, and 
treatment. The ADRs that were not defined by a laboratory test, the 
physician documented in patient chart based on clinical expertise 
and patient-reported signs or symptoms. All medical records were 
treated with complete confidentiality.  
Data analysis 
The data were analysed using SPSS 25 and G Power 3.1.9.2. 
Descriptive statistics like frequency and percent were used to 
summarize the data.  
Severity assessment of ADRs was done by using the Modified Scale 
of Hartwig and Siegel into the mild, moderate, and severe categories. 
Causality assessment of adverse drug reaction was obtained with 
WHO-UMC criteria and Naranjo’s causality algorithm. Also assessed 
the preventability using Modified Schumock and Thornton scale. 
Ethics  
The scientific committee granted the conductance of the study and 
Ethical approval was obtained from the Institutional Human Ethics 
Committee (IHEC) via no: 012/IHEC/10/2019/NCP. Permission to 
conduct this study was additionally sought from the State and 
District TB office after submitting the IHEC approval with the 
proposed plan. Later OR committee and Directorate of Health 
Science solemnly approved the study with clearance No: 
281/STC/DHS/2019. 
RESULTS 
A total of 146 participants who were on treatment during 2016-
2019 were enrolled in this study. Among 146 DR-TB patients,115 
(78.76%) were males and 31 (21.23%) were females. Most of the 
study participants (47.9%) were in the age group of 46-65 y 
followed by 30.8% in the age group of 26-45 y (fig. 1). 
 
 
Fig. 1: Distribution of DR-TB patients according to sex and age 
 
Out of 146 patients, 91 patients have experienced about 208 adverse 
drug reactions of various types and there were many more ADRs that 
caused a change in lab data of individual patients, among which the 
most prevalent ones are included in table 1. Among all the ADRs 
extracted the most common ADR was found to be gastritis (12.98%), 
ototoxicity (10%), vomiting (5.76%), QT prolongation (4.8%), anemia 
(4.32%), insomnia (4.32%), joint pain (3.84%), nephrotoxicity 
(3.36%), psychosis (2.88%) and hypothyroidism (2.88%). It was 
found that males (82.69%) experienced higher ADR than females 
(17.30%) which might be due to higher male participants. 
  
 
Fig. 2: WHO-UMC causality assessment, On doing severity assessment of ADR by using modified hartwig and seigel scale, 23.07% were 
moderate reaction (level 4b) and 17.3% were mild category (level 2) 
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Table 1: Frequency of adverse drug reaction 
ADR Male Female Total 
Abdominal discomfort 2 (100%) 0 2 (0.96%) 
Abnormal ECG 0 1 (100%) 1 (0.48%) 
Acute kidney injury 4 (80%) 1 (20%) 5 (2.40%) 
Anaemia 5 (55.5%) 4 (44.4%) 9 (4.32%) 
Anisopoikilocytosis 1 (100%) 0 1 (0.48%) 
Anxiety 2 (100%) 0 2 (0.96%) 
Arrhythmia 1 (100%) 0 1 (0.48%) 
Arthralgia 3 (75%) 1 (25%) 4 (1.92%) 
Arthritis 3 (100%) 0 3 (1.44%) 
Bleeding 1 (100%) 0 1 (0.48%) 
Blurred vision 4 (100%) 0 4 (1.92%) 
Breathing difficulty 2 (100%) 0 2 (0.96%) 
Cystitis 1 (100%) 0 1 (0.48%) 
Depression 1 (100%) 0 1 (0.48%) 
Gall stone 1 (100%) 0 1 (0.48%) 
Gastritis 23 (85.1%) 4 (14.8%) 27 (12.98%) 
Giddiness 5 (100%) 0 5 (2.40%) 
Gynaecomastia 1(100%) 0 1 (0.48%) 
Hallucination 2 (100%) 0 2 (0.96%) 
Hematologic abnormality 0 1 (100%) 1 (0.48%) 
Hyperuricemia 3 (60%) 2 (40%) 5 (2.40%) 
Hyperglycaemia 1(100%) 0 1 (0.48%) 
Hyperkalaemia 1 (100%) 0 1 (0.48%) 
Hyperpigmentation 1(100%) 0 1 (0.48%) 
Hyponatremia 3(100%) 0 3 (1.44%) 
Hypoproteinaemia 1(100%) 0 1 (0.48%) 
Hypotension 0 1 (100%) 1 (0.48%) 
Hypothyroidism 4 (66.6%) 2 (33.33%) 6 (2.88%) 
Insomnia 8 (88.8%) 1 (11.11%) 9 (4.32%) 
Itching 3 (75%) 1 (25%) 4 (1.92%) 
Joint pain 7(87.5%) 1(12.5%) 8 (3.84%) 
LFT elevation 3(100%) 0 3 (1.44%) 
Mood swings 1(100%) 0 1 (0.48%) 
Nausea 4 (100%) 0 4 (1.92%) 
Nephrotoxicity 6 (85.71%) 1 (14.28%) 7 (3.36%) 
Numbness 2 (100%) 0 2 (0.96%) 
Optic neuropathy 1 (100%) 0 1 (0.48%) 
Ototoxicity 18 (85.71%) 3 (14.28%) 21 (10%) 
Paraesthesia  1(100%) 0 1 (0.48%) 
Pedal oedema 2(100%) 0 2 (0.96%) 
Peripheral neuropathy 4(100%) 0 4 (1.92%) 
Photosensitivity 1 (100%) 0 1 (0.48%) 
Psychosis 3 (50%) 3 (50%) 6 (2.88%) 
QT prolongation 10(100%) 0 10 (4.8%) 
Sinus tachycardia 0 2(100%) 2 (0.96%) 
Throat congested 1(100%) 0 1 (0.48%) 
Tiredness/weakness 3 (60%) 2 (40%) 5 (2.4%) 
Tremor 1 (100%) 0 1 (0.48%) 
UTI 1 (50%) 1 (50%) 2 (0.96%) 
Vertigo 5 (83.33%) 1 (16.66%) 6 (2.88%) 
Vomiting 9 (75%) 3 (25%) 12 (5.76%) 
Watery eyes 1(100%) 0 1 (0.48%) 
Xeroderma 1(100%) 0 1 (0.48%) 
Total 172 (82.69%) 36 (17.30%) 208 
 
The main action taken in patients detected with ADR was to 
withhold, stop, continue, or replace the culprit drug and provide 
supportive treatment. Gastrointestinal manifestations are frequently 
observed with all the DR-TB regimens. The most common causative 
agents are Kanamycin (24.03%) followed by cycloserine (Cs) 
(8.17%) and ethambutol (5.76%)(table 2). Out of 15 patients 
experiencing psychiatric symptoms with Cs, six patients required 
withdrawal and were substituted mainly with PAS. 
  
Table 2: Drug details regarding ADR 
Drug ADR Withhold drug Stop drug Continued  Sub drug Treatment 
Isoniazid  Hyperpigmentation (1) 
Peripheral neuropathy (2) 















Silymarin, ursodeoxycholic acid-1 
Ethambutol  Hyperuricemia (3) 
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Blurred vision (3) 
Psychosis (1) 
Watery eyes (1) 



























Pyrazinamide  Hyperuricemia (5) 






















Severe itching (1) 
Swelling of face (1) 













































Levofloxacin Giddiness (1) 
Numbness (1) 




























Moxifloxacin QT prolongation (5) 




















































































Bedaquiline  Sinus tachycardia (1) 









Aspirin, Sorbitrate,  
Nil 
Delamanid QT prolongation(1) 0 1 0 0 Nil 
AKI-acute kidney injury, UTI-Urinary tract infection, LFT-Liver function test. Causality assessment of all ADRs was done by using both Naranjo’s 
causality assessment and the WHO-UMC scale. The assessment by Naranjo’s scale revealed that 6(2.8%) adverse drug reactions were categorized as 
definite, 141(67.8%) as probable, and 61(29.32%) as possible reactions.  
 
Table 3: Categorizationof ADR by naranjo’s causality assessment 
Causality  NO. OF ADR (%) 
Definite  6(2.8%) 
Probable  141(67.8%) 
Possible  61(29.32%) 
The assessment done by using the WHO-UMC scale showed that the majority of the ADR (44%) falls under the probable category.  
 
Table 4: Severity assessment of ADRs by modified hartwig and seigel scale 
Severity  No. of ADR Percentage (%) 
Mild level 1 33 15.86 
Level 2 36 17.30 
Moderate  Level 3 24 11.53 
Level 4 a 19 9.13 
Level 4 b 48 23.07 
Severe Level 5 3 1.44 
Level 6 33 15.9 
Level 7 12 5.76 
Preventability assessment was based on Schumock and Thronton scale and showed that the majority (32.2%) were not preventable while only 2 
(0.96%) were definitely preventable ADRs (fig. 3). 
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Fig. 3: Preventability assessment of ADRs by schumock and thronton scale 
 
DISCUSSION 
DR-TB is difficult to treat day by day as it requires long-term 
exposure and is associated with greater toxicity effects. ADR 
associated with these drugs may further complicate the picture and 
is a main challenging factor. The present observational study has 
evaluated the pattern and frequency of adverse drug reactions and 
assessed their severity, causality, and preventability in patients 
receiving treatment for DR-TB. The demographic characteristics of 
patients were compared to previous studies. In most reports’ 
females are at high risk for DR-TB but in the present study males 
and females have equal chances of getting DR-TB. 
In table 1 the DR-TB patients were classified into 5 categories (age 
group was classified according to study: Population-Based Drug 
Resistance Surveillance of Multidrug-Resistant Tuberculosis in 
Taiwan, 2007-2014) according to their age. More patients were seen 
in the age group 46-65 of male categories and 26-45 age group of 
female categories. By comparing the study conducted by Mehari K et 
al. that claims MDR TB to be more prevalent among the age group 
15-44 ie. within the productive age group, this study witnessed more 
MDR-TB cases outside this range [10]. 
More males than females suffer from tuberculosis worldwide. This 
study also indicates that there were more male cases with DR TB than 
females and therefore, males have higher incidences of adverse events 
than female patients. This is because men were vulnerable to ADR due 
to economic responsibility and environmental exposure to resistant 
strain and also as they recorded more addictions towards smoking, 
alcohol intake, which results in the weakening of immunity [11]. 
In the present study, a total number of 208 ADRs were observed in 
91 patients, as more than one ADR has been observed in 41 patients. 
The occurrence of ADR (table 1) associated with gastritis being the 
most common is persistent with other reports too [12]. Even though 
gastritis being the most predominant ADR in this study, the 
occurrence is lower as compared to other existing studies (12.98%), 
which might be due to under-reporting by patients and as they rely 
on OTC medications for symptomatic relief [6]. These disturbances 
are most pronounced after treatment with ethambutol and PAS, 
even though all drugs cause a similar effect to an extent. Most GI side 
effects can be managed without stopping the drug by decreasing the 
dose, dividing the dose, or using antiemetics. If the GI symptoms 
were not severe, additional H2 receptor blockers or antiemetic 
agents were incorporated into the regimen [12]. 
Ototoxicity was the second most common ADR and the increased 
rate of ototoxicity may be due to higher dose and long-term 
exposure (up to 12 mo). The study conducted by Shibeshi W et al. 
has proved the association of ototoxicity by using kanamycin and 
other aminoglycosides. Kanamycin is primarily cochleo-toxic; 
however, long-term use may result in permanent hearing loss and 
damage to the vestibular apparatus, which leads to dizziness, ataxia, 
or nystagmus. The mechanism underlying is, on chronic 
administration of aminoglycosides generates free radicals within the 
inner ear, with subsequent permanent damage to sensory cells and 
neurons, resulting in permanent hearing loss. Drug-induced 
ototoxicity can be triggered by several conditions such as smoking 
and alcohol use, prolonged duration of treatment, malnutrition, 
aging, some bacterial infections, and genetic factors [13]. 
Km is the most ADR-causing drug that induces ototoxicity, 
nephrotoxicity, and vertigo as they were used for a longer duration. 
The action mainly taken for Kanamycin-induced ototoxicity was the 
withdrawal of Km, which was replaced with PAS. Ototoxicity was the 
major ADR that requires drug withdrawal. In contrary to other 
studies(Amin S et al.) the second and third most common causal 
agent was cycloserine and ethambutol in this present study [5]. 
Severe psychiatric symptoms and psychosis, including 
hallucinations, anxiety, depression, euphoria, behavioral disorders, 
and suicidal ideation or attempts, have been reported to occur in 
individuals receiving Cs [14]. Thus, Cs-associated neurotoxicity is 
likely due to diminished central nervous system production of 
gamma-aminobutyric acid caused by inhibition of glutamic 
decarboxylase [15]. The study by Jaramillo E reports that if 
psychiatric disturbances occur in patients receiving cycloserine, the 
drug was supposed to be stopped and substituted with PAS leading 
to rapid recovery of mental status and with no recurring symptoms 
[16]. Pyrazinamide and ethambutol have been associated to cause an 
increase in uric acid levels. Severe hyperuricemia can lead to renal 
failure. Hence, uric acid level measurement should be done 
particularly in patients with pre-existing conditions [17]. 
Hepatotoxicity was the most common ADR by anti-TB drugs and this 
study does not report any cases. The drug-induced hepatotoxicity is 
highly variable and ranges from an asymptomatic elevation of liver 
enzymes into fulminant hepatic failure. It is also important that TB 
itself can invade the liver and result in abnormal liver function [12]. 
When there is hepatotoxicity associated with the use of a drug, the 
drug leading to hepatotoxicity is suspended until liver function tests 
return to normal limits. Gradually introducing the drugs by 
administering them in increasing numbers and dosages is 
recommended as per guidelines. The drugs most commonly 
associated with hepatotoxicity like Isoniazid, should be used 
cautiously. Pyrazinamide causes arthralgia, arthritis, and gout. 
Symptoms of pyrazinamide-induced arthralgia had been reduced 
and treated with NSAIDs, although pyrazinamide should be 
withdrawn if acute gout attacks occur.[12]In our present study 
ethionamide can cause gynecomastia and hypothyroidism. It can 
cause hypothyroidism by inhibiting thyroid hormone synthesis 
through a mechanism of iodine organification inhibition [18]. 
To establish a causal relationship between a drug and an adverse 
event, it is necessary to carry out a causality assessment. In the 
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present study, a causality assessment was done using Naranjo’s and 
WHO-UMC algorithms.  
Naranjo’s scale was based on the points given for each question 
which comprise of ten questions that are answered ‘Yes’, ‘No’ or ‘Do 
not Know’. After totaling the points, they were categorized into 
definite (≥ 9), probable (5-8), possible (1-4) and unlikely (≤0) [19]. 
Majority of the ADR belongs to the probable (67.8%) category while 
29.32% were possible reactions (table no 3) which is contrary to the 
study conducted by Shinde MP et al. [6]. 
In the WHO-UMC scale for assessing ADRs categories like certain, 
probable, possible, unlikely, unclassified, and unclassifiable were 
considered. Based on that, 44% were probable, 36% possible 
reaction, 17% were certain and 3% were unlikely, which is similar 
to other studies conducted by BJ M K et al. [19]. 
For the proper management of ADR, it is better to study the severity 
of ADR. Modified Hartwig and Seigel scale was used to assess the 
severity which categorizes the ADR into mild, moderate, and severe. 
In the present study majority of the ADR (23.07%) were moderate 
level 4b and 17.3% were mild (table 4), which is similar to the study 
conducted by Shindhe MP et al. [6]. 
Schumock and Throton scale was established for assessing the 
preventability of ADR. Using this scale, 66.82% were classified as 
non-preventable, 32.2% were probably preventable and 0.96% were 
definitely preventable (fig. 3).  
Due to its retrospective nature, we have missed the opportunity of 
direct patient interaction and thus, the details of ADR were obtained 
only from the medical records of the patients. Many of the ADRs 
were under-reported and it has influenced this study results and the 
study could not correlate the laboratory values with the ADR. 
CONCLUSION 
ADR stands to be a great de-motivator for the patients which results 
in an overall decrease in adherence to treatment. Therefore, there is 
an urgent need for regular monitoring, timely reporting, and 
adequate management of ADR. Gastritis is the most common ADR 
followed by ototoxicity and vomiting. Kanamycin and cycloserine 
are the major culprit drugs that require drug withdrawal and 
replacement with PAS. As the number of drugs increase, a probable 
increase in the ADRs is also observed; thus this study concludes that 
there is an urgent need for proper monitoring and management of 
ADR to increase patient compliance. 
LIMITATIONS  
Our study being retrospective, has missed the opportunity to 
obtain direct patient information and incomplete follow-up 
details. Some of the ADRs were under-reported because of, lack of 
awareness about the ADR among patients. Only significant ADR 
has been recorded.  
AUTHORSHIP 
All authors contributed equally to the study and the article. 
ACKNOWLEDGMENT 
We express our gratitude towards state and district Tuberculosis 
coordinators for their permission, support, and assistance given 
during the project period. 
FUNDING 
No funding was received by the authors. 
AUTHORS CONTRIBUTIONS 
All the authors have contributed equally. 
CONFLICT OF INTERESTS 
The authors declare that there is no conflict of interest. 
REFERENCES 
1. Kurz SG, Furin JJ, Bark CM. Drug-resistant tuberculosis: 
challenges and progress. Infectious Disease Clin 2016;30:509-22. 
2. World Health Organization. Stop TB Initiative (World Health 
Organization). Treatment of tuberculosis: guidelines. World 
Health Organization; 2010. 
3. Nusrath Unissa A, Hanna LE, Swaminathan S. A note on 
derivatives of isoniazid, Rifampicin, and pyrazinamide showing 
activity against resistant Mycobacterium tuberculosis. Chem 
Biol Drug Des 2016;87:537-50. 
4. Prasad R, Singh A, Gupta N. Adverse drug reactions in 
tuberculosis and management. Indian J Tuberc 2019;66:520-32. 
5. Amin S, Mishra V, Mira D, Rajesh S. Pattern of adverse drug 
reactions and its potential impact on drug-resistant 
tuberculosis patients at a tertiary care teaching hospital in 
Western India. Clin J Pharmacol Pharmacother 2018;1:15-20. 
6. Shinde MP, Halasawadekar NR, Ramanand SJ, Pore SM, 
Ramanand JB, Patil PT, et al. A study of adverse drug reactions 
in patients receiving treatment for multi-drug resistant 
tuberculosis. Int J Basic Clin Pharmacol 2017;34:354-8. 
7. Isaakidis P, Varghese B, Mansoor H, Cox HS, Ladomirska J, 
Saranchuk P, et al. Adverse events among HIV/MDR-TB co-
infected patients receiving antiretroviral and second-line anti-
TB treatment in Mumbai, India. PloS One 2012;11:e40781. 
8. Gualano G, Mencarini P, Musso M, Mosti S, Santangelo L, 
Murachelli S, et al. Putting in harm to cure: drug-related 
adverse events do not affect the outcome of patients receiving 
treatment for multidrug-resistant tuberculosis. Experience 
from a tertiary hospital in Italy. PloS One 2019;14:e0212948. 
9. Hire R, Kale AS, Dakhale GN, Gaikwad N. A prospective, 
observational study of adverse reactions to drug regimen for 
multi-drug resistant pulmonary tuberculosis in central India. 
Mediterranean J Hematol Infectious Diseases 2014;6:e2014061. 
10. Mehari K, Asmelash T, Hailekiros H, Wubayehu T, Godefay H, 
Araya T, et al. Prevalence and factors associated with 
multidrug-resistant tuberculosis (MDR-TB) among 
presumptive MDR-TB patients in tigray region, Northern 
Ethiopia. Canadian J Inf Diseases Med Microbiol 2019;1-8. 
https://doi.org/10.1155/2019/2923549. 
11. Bistline KL. Does the inclusion of the cost and burden of 
adverse drug reactions associated with drug-resistant TB 
treatment affect the incremental cost-effectiveness of new 
treatment regimens? A case study from the introduction of 
bedaquiline in South Africa National TB Programme (Doctoral 
dissertation, University of Cape Town); 2018. 
12. Yang TW, Park HO, Jang HN, Yang JH, Kim SH, Moon SH, et al. 
Side effects associated with the treatment of multidrug-
resistant tuberculosis at a tuberculosis referral hospital in 
South Korea: a retrospective study. Medicine 2017;96:e7482. 
13. Shibeshi W, Sheth AN, Admasu A, Berha AB, Negash Z, Yimer G. 
Nephrotoxicity and ototoxic symptoms of injectable second-line 
anti-tubercular drugs among patients treated for MDR-TB in 
Ethiopia: a retrospective cohort study. BMC Pharmacol Toxicol 
2019;20:31. 
14. Kennedy NA, Oluwaseun A, Denis AD, Chukwuemeka SP. 
Cycloserine induced-psychosis in a 22-year old male pharmacy 
student: a case report. Am J Psychiatry Neurosci 2016;4:1-4. 
15. Dere E, Zlomuzica A, Silva MD, Ruocco LA, Sadile AG, Huston JP. 
Neuronal histamine and the interplay of memory, reinforcement 
and emotions. Behavioural Brain Res 2010;215:209-20. 
16. Jaramillo E. Guidelines for the programmatic management of 
drug-resistant tuberculosis. World Health Organization; 2008. 
17. Pham AQ, Doan A, Andersen M. Pyrazinamide-induced 
hyperuricemia. Pharm Ther 2014;39:695-715. 
18. Drucker D, Eggo MC, Salit IE, Burrow GN. Ethionamide-lnduced 
goitrous hypothyroidism. Annals Int Med 1984;100:837-9. 
19. BJ MK, Mathew S, Ramesh S, Hymavathi R, Srikanth MS. Causality 
assessment of adverse drug reactions in tuberculosis patients 
who are on directly observed treatment short-course strategy in 
mysore district. Indian J Pharm Practice 2013;6:22-6. 
 
